A new regenerative medicines company deploying regulatory T cells as potential therapies was launched in the US on 23 June with a Series A financing of $95 million. Abata Therapeutics plans to treat patients with severe autoimmune and inflammatory diseases, starting with non-relapsing multiple sclerosis, a disease for which there are no approved therapies. The Series A funding was provided by a syndicate led by Third Rock Ventures. Other investors included the biotech company ElevateBio LLC and the charity Juvenile Diabetes Research Foundation.
